@article{3100428,
    title = "The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review",
    author = "Daniilopoulou, I. and Vlachou, E. and Lambrou, G.I. and Ntikoudi, A. and Dokoutsidou, E. and Fasoi, G. and Govina, O. and Kavga, A. and Tsartsalis, A.N.",
    journal = "MEDICINA-LITHUANIA",
    year = "2022",
    volume = "58",
    number = "2",
    publisher = "MDPI",
    doi = "10.3390/medicina58020224",
    keywords = "antidiabetic agent, animal;  case control study;  complication;  fracture;  glucose blood level;  human;  metabolism;  non insulin dependent diabetes mellitus;  randomized controlled trial (topic), Animals;  Blood Glucose;  Case-Control Studies;  Diabetes Mellitus, Type 2;  Fractures, Bone;  Humans;  Hypoglycemic Agents;  Randomized Controlled Trials as Topic",
    abstract = "Background and Objectives: The association between diabetes mellitus and increased risk of bone fractures has led to the investigation of the impact of antidiabetic drugs on bone metabolism. Glucagon-like peptide-1 receptor agonists (GLP1RAs) are a relatively novel and promising class of anti-hyperglycemic drugs. In addition to their blood glucose lowering action, GLP1RAs seem to have additional pleiotropic properties such as a beneficial skeletal effect; although the underlying mechanisms are not completely understood. The present systematic review summarizes current evidence about GLP1RAs and their effects on bone metabolism and fracture. Methods: An extensive literature search was conducted based on electronic databases namely, PubMed, Google Scholar and Cochrane Central Register of Controlled Trials (CENTRAL) through October 2019 to January 2020 for articles related to bone mineral density, diabetes mellitus and GLP1RAs. We included articles published in English. Finally, we included four randomized controlled trials, three meta-analyses, a case-control study and a population-based cohort analysis. Results: Based on the articles included, the animal studies indicated the salutary skeletal effects of GLP1RAs in opposition to what has been commonly observed in human studies, showing that these agents have no impact on bone mineral density (BMD) and the turnover markers. Moreover, it was demonstrated that GLP1 was not associated with fracture risk as compared to other anti-hyperglycemic drugs. Conclusions: Findings from this systematic review have demonstrated the neutral impact of GLP1RAs on BMD. Moreover, further double-blind randomized controlled trials are needed to draw more meaningful and significant conclusions on the efficacy of GLP1RAs on BMD. © 2022 by the authors. Licensee MDPI, Basel, Switzerland."
}